<DOC>
	<DOCNO>NCT01391052</DOCNO>
	<brief_summary>Problematic uterine bleed insertion LNG IUS well document side effect . The levonorgestrel intrauterine system ( LNG IUS ) approve treatment heavy menstrual bleeding ( HMB ) FDA October 2009 . To reduce incidence severity post-insertional uterine bleeding , pretreatment norethindrone acetate may effectively slough endometrium prior insertion LNG IUS .</brief_summary>
	<brief_title>Pretreatment With Norethindrone Acetate Prior Levonorgestrel IUS Insertion Heavy Menstrual Bleeding</brief_title>
	<detailed_description>This study examine whether pretreatment oral norethindrone acetate prior insertion hormonal intrauterine device affect post-insertional uterine bleeding . The subject enrol study document heavy menstrual bleeding ( HMB ) desire levonorgestrel intrauterine system ( LNG IUS ) ( MirenaÂ® , Bayer , Inc. Pittsburgh , PA ) symptomatic relief . HMB study define heavy bleeding regular interval least 20-40 day apart . Subjects randomize one two group . One group receive norethindrone acetate two consecutive month prior LNG IUS insertion group proceed direct insertion LNG IUS hormonal pre-treatment . Subjects follow period 180 day post LNG IUS insertion . Bleeding pattern record daily .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Menorrhagia</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Norethindrone acetate</mesh_term>
	<mesh_term>Norethindrone</mesh_term>
	<criteria>You must 1845 year old You Heavy Periods You pregnant You currently use hormonal contraception hormonal therapy You history pelvic inflammatory disease ( normal pregnancy since ) You infect abortion within last three month You abnormal cancerous cell cervix uterus You actine infection genital organ Known suspected breast cancer Active liver disease tumor Allergy levonorgestrel norethindrone You currently deep vein thrombosis , pulmonary embolism , history condition currently active recent ( within past year ) arterial thromboembolic disease ( stroke myocardial infarction ) condition</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Intrauterine system</keyword>
	<keyword>reproductive age</keyword>
	<keyword>menstrual bleeding</keyword>
</DOC>